| __timestamp | AstraZeneca PLC | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 2854000000 |
| Thursday, January 1, 2015 | 5997000000 | 3014000000 |
| Friday, January 1, 2016 | 5890000000 | 5098000000 |
| Sunday, January 1, 2017 | 5757000000 | 3734000000 |
| Monday, January 1, 2018 | 5932000000 | 5018000000 |
| Tuesday, January 1, 2019 | 5958000000 | 9106000000 |
| Wednesday, January 1, 2020 | 5991000000 | 5039000000 |
| Friday, January 1, 2021 | 9736000000 | 5363000000 |
| Saturday, January 1, 2022 | 9762000000 | 4977000000 |
| Sunday, January 1, 2023 | 10935000000 | 6923000000 |
Unleashing insights
In the competitive landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, AstraZeneca PLC and Gilead Sciences, Inc. have been at the forefront of this race. From 2014 to 2023, AstraZeneca's R&D expenses surged by approximately 96%, peaking in 2023 with a remarkable $10.9 billion. This represents a strategic focus on expanding their drug pipeline and enhancing therapeutic offerings.
Conversely, Gilead Sciences exhibited a more fluctuating pattern, with a notable spike in 2019, where R&D spending reached $9.1 billion, before stabilizing around $6.9 billion in 2023. This reflects Gilead's adaptive strategy in response to market demands and innovation challenges. As these giants continue to invest heavily in R&D, the pharmaceutical industry watches closely, anticipating groundbreaking advancements that could redefine healthcare.
AbbVie Inc. or Gilead Sciences, Inc.: Who Invests More in Innovation?
Cost of Revenue Trends: AstraZeneca PLC vs Gilead Sciences, Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Gilead Sciences, Inc. and Madrigal Pharmaceuticals, Inc.
R&D Insights: How Gilead Sciences, Inc. and Axsome Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Gilead Sciences, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Perrigo Company plc
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.